Home > Report Listing > Global Cancer/Tumor Profiling Market to reach USD 12 billion by 2026.
MedicalDevices
Global Cancer/Tumor Profiling Market to reach USD 12 billion by 2026.
Cancer/Tumor Profiling Report provides a comprehensive glance on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2026 based on revenue (USD Billion).
54
Global Cancer/Tumor Profiling Market is valued approximately USD 5.9 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 10.7 % over the forecast period 2019-2026. Growing focus for the development of personalized medicine, growing utility of biomarkers in tumor profiling and increasing R&D investments in cancer are some major trends that are responsible for the wide adoption of Cancer/Tumor Profiling globally. Global Cancer/Tumor Profiling market is majorly driven by increasing prevalence of cancer globally. The World Cancer Research Fund International (WCRFI) estimates that, nearly 2 million new cases of breast cancer are being detected every year and breast cancer is considered as the most common form of cancer in women globally. American Cancer Research Society (ACRS) anticipates by 2030, incident rate of breast cancer is expected to reach over 9.9million cases with over 5.5million annual deaths, primarily due to aging population. Incident rates of breast cancer are highest (46% in 2016) amongst women aged between 45-65 years across the globe. ACRS studies reveals that, with aging population prevalence rate of breast cancer amongst elderly women aged 55 years and above is bound to increase. Breast cancer represents 12% of all new cases of cancer amongst women in 2016, according to WCRFI. Europe leads the world with highest number (25% in 2016) of new breast cancer cases in the world followed by North America and Asia Pacific according to National Cancer Institute (NCI), USA. Belgium, Denmark, France, Netherlands, Bahamas and USA are countries with highest rates of breast cancer in the world according to WCRFI survey in 2016. Global economic burden due to breast cancer stood at $5.7billion in 2016 according to ACRS. However, ACRS estimates, the economic burden on breast cancer is anticipated to reach over $8 billion by 2026. Increasing number of breast cancer cases would supplement global cancer/tumor profiling market for the forecasted period. However, lack of skilled professionals is a major factor that impede the growth of the Cancer/Tumor Profiling market over the forecast period. On the basis of segmentation, the Cancer/Tumor Profiling market is segmented into technology, cancer type and application. The technology segment of global Cancer/Tumor Profiling market is classified into immunoassays, hybridization, next generation sequencing, mass spectrometry and other technologies of which immunoassays accounted for the largest market share owing to its cost-effectiveness, high sensitivity as well as technological advancements in this technology would propel the growth of the immunoassays. Based on the cancer type segment, the cancer/tumor profiling is bifurcated into breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma cancer and other cancer of which breast cancer segment holds the leading position owing to the increased awareness about breast cancer diagnosis, rising prevalence of breast cancer. The application segment includes clinical application and research application. The regional analysis of Cancer/Tumor Profiling Market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America have occupied major share in the global Cancer/Tumor Profiling market. The major reasons for the dominance of North America are rising prevalence of cancer along with the high rate of adoption in this region. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific region is witnessed owing to rising number of contract research organizations (CROs), growing demand for better healthcare services and increasing incidences of cancer. The leading market players mainly include- Illumina, Inc. Qiagen N.V. Neogenomics Laboratories, Inc. HTG Molecular Diagnostics, Inc. Genomic Health Inc. Caris Life Sciences Helomics Corporation Nanostring Technologies, Inc. Oxford Gene Technology Ribomed Biotechnologies, Inc. The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Technology: Immunoassays Hybridization Next Generation Sequencing Mass Spectrometry Other Technologies By Cancer Type: Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Cancer Others Cancer By Application: Clinical Application Research Application By Regions: North America U.S. Canada Europe UK Germany ROE Asia Pacific China India Japan ROAPEC LAMEA Brazil Mexico ROW Middle East & Africa Furthermore, years considered for the study are as follows: Historical year ? 2016, 2017 Base year ? 2018 Forecast period ? 2019 to 2026 Target Audience of the Global Cancer/Tumor Profiling Market in Market Study: Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investors
Chapter 1.Executive Summary 1.1.Market Snapshot 1.2.Key Trends 1.3.Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion) 1.3.1.Urgent Care Center Market, by Service, 2016-2026 (USD Billion) 1.3.2.Urgent Care Center Market, by Ownership, 2016-2026 (USD Billion) 1.3.3.Urgent Care Center Market, by Region, 2016-2026 (USD Billion) 1.4.Estimation Methodology 1.5.Research Assumption Chapter 2.Global Urgent Care Center Market Definition and Scope 2.1.Objective of the Study 2.2.Market Definition & Scope 2.2.1.Industry Evolution 2.2.2.Scope of the Study 2.3.Years Considered for the Study 2.4.Currency Conversion Rates Chapter 3.Global Urgent Care Center Market Dynamics 3.1.See Saw Analysis 3.1.1.Market Drivers 3.1.2.Market Challenges 3.1.3.Market Opportunities Chapter 4.Global Urgent Care Center Market Industry Analysis 4.1.Porter?s 5 Force Model 4.1.1.Bargaining Power of Buyers 4.1.2.Bargaining Power of Suppliers 4.1.3.Threat of New Entrants 4.1.4.Threat of Substitutes 4.1.5.Competitive Rivalry 4.1.6.Futuristic Approach to Porter?s 5 Force Model 4.2.PEST Analysis 4.2.1.Political Scenario 4.2.2.Economic Scenario 4.2.3.Social Scenario 4.2.4.Technological Scenario 4.3.Key Buying Criteria (On Demand) 4.4.Regulatory Framework (On Demand) 4.5.Investment Vs Adoption Scenario (On Demand) 4.6.Analyst Recommendation & Conclusion Chapter 5.Global Cancer/Tumour Profiling Market, By Technology 5.1.Market Snapshot 5.2.Market Performance - Potential Model 5.3.Global Cancer/Tumour Profiling Market, Sub Segment Analysis 5.3.1. Immunoassays 5.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 5.3.1.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 5.3.2. Hybridization 5.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 5.3.2.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 5.3.3.Next Generation Sequencing 5.3.3.1.Market estimates & forecasts, 2016-2026 (USD Billion) 5.3.3.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 5.3.4.Mass Spectrometry 5.3.4.1.Market estimates & forecasts, 2016-2026 (USD Billion) 5.3.4.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 5.3.5. Other Technologies 5.3.5.1.Market estimates & forecasts, 2016-2026 (USD Billion) 5.3.5.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) Chapter 6.Global Cancer/Tumour Profiling Market, By Cancer Type 6.1.Market Snapshot 6.2.Market Performance - Potential Model 6.3.Global Cancer/Tumour Profiling Market, Sub Segment Analysis 6.3.1. Lung Cancer 6.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 6.3.1.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 6.3.2. Breast Cancer 6.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 6.3.2.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 6.3.3. Colorectal Cancer 6.3.3.1.Market estimates & forecasts, 2016-2026 (USD Billion) 6.3.3.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 6.3.4. Prostate Cancer 6.3.4.1.Market estimates & forecasts, 2016-2026 (USD Billion) 6.3.4.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 6.3.5. Melanoma Cancer 6.3.5.1.Market estimates & forecasts, 2016-2026 (USD Billion) 6.3.5.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 6.3.6. Other Cancers 6.3.6.1.Market estimates & forecasts, 2016-2026 (USD Billion) 6.3.6.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) Chapter 7.Global Cancer/Tumour Profiling Market, By Application 7.1.Market Snapshot 7.2.Market Performance - Potential Model 7.3.Global Cancer/Tumour Profiling Market, Sub Segment Analysis 7.3.1. Clinical Application 7.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 7.3.1.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 7.3.2. Research Application 7.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 7.3.2.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) Chapter 8.Global Cancer/Tumour Profiling Market, by Regional Analysis 8.1.Cancer/Tumour Profiling Market, Regional Market Snapshot (2016-2026) 8.2.North America Cancer/Tumour Profiling Market Snapshot 8.2.1.U.S. 8.2.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.2.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.2.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.2.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.2.2.Canada 8.2.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.2.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.2.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.2.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.Europe Cancer/Tumour Profiling Market Snapshot 8.3.1.U.K. 8.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.3.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.2.Germany 8.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.3.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.3.Rest of Europe 8.3.3.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.3.3.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.3.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.3.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.Asia Cancer/Tumour Profiling Market Snapshot 8.4.1.China 8.4.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.4.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.2.India 8.4.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.4.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.3.Japan 8.4.3.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.4.3.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.3.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.4.Rest of Asia Pacific 8.4.4.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.4.4.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.4.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.4.4.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.5.Latin America Cancer/Tumour Profiling Market Snapshot 8.5.1.Brazil 8.5.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.5.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.5.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.5.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.5.2.Mexico 8.5.2.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.5.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.5.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.5.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.6.Rest of The World 8.6.1.Middle East and Africa 8.6.1.1.Market estimates & forecasts, 2016-2026 (USD Billion) 8.6.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.6.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 8.6.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion) Chapter 9.Competitive Intelligence 9.1.Company Market Share (Subject to Data Availability) 9.2.Top Market Strategies 9.3.Company Profiles 9.3.1. Illumina, Inc. 9.3.1.1.Overview 9.3.1.2.Financial (Subject to Data Availability) 9.3.1.3.Product Summary 9.3.1.4.Recent Developments 9.3.2. Qiagen N.V. 9.3.3. Neogenomics Laboratories, Inc. 9.3.4. HTG Molecular Diagnostics, Inc. 9.3.5. Genomic Health Inc. 9.3.6. Caris Life Sciences 9.3.7. Helomics Corporation 9.3.8. Nanostring Technologies, Inc. 9.3.9. Oxford Gene Technology 9.3.10.Ribomed Biotechnologies, Inc. Chapter 10.Research Process 10.1.Research Process 10.1.1.Data Mining 10.1.2.Analysis 10.1.3.Market Estimation 10.1.4.Validation 10.1.5.Publishing 10.1.6.Research Assumption
TABLE 1.LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL CANCER/TUMOR PROFILING MARKET TABLE 2.LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL CANCER/TUMOR PROFILING MARKET TABLE 3.GLOBAL CANCER/TUMOR PROFILING MARKET, REPORT SCOPE TABLE 4.YEARS CONSIDERED FOR THE STUDY TABLE 5.EXCHANGE RATES CONSIDERED TABLE 6.GLOBAL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION) TABLE 7.GLOBAL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY TECHNOLOGY 2016-2026 (USD BILLION) TABLE 8.GLOBAL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY CANCER TYPE 2016-2026 (USD BILLION) TABLE 9.GLOBAL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY APPLICATION 2016-2026 (USD BILLION) TABLE 10.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 11.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 12.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 13.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 14.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 15.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 16.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 17.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 18.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 19.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 20.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 21.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 22.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 23.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 24.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 25.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 26.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 27.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 28.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 29.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 30.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 31.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 32.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 33.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 34.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 35.GLOBAL CANCER/TUMOR PROFILING MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 36.U.S. CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 37.U.S CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 38.U.S CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 39.U.S. CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 40.CANADA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 41.CANADA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 42.CANADA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 43.CANADA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 44.UK CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 45.UK CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 46.UK CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 47.UK CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 48.GERMANY CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 49.GERMANY CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 50.GERMANY CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 51.GERMANY CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 52.ROE CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 53.ROE CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 54.ROE CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 55.ROE CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 56.CHINA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 57.CHINA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 58.CHINA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 59.CHINA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 60.INDIA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 61.INDIA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 62.INDIA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 63.INDIA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 64.JAPAN CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 65.JAPAN CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 66.JAPAN CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 67.JAPAN CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 68.ROAPAC CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 69.ROAPAC CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 70.ROAPAC CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 71.ROAPAC CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 72.BRAZIL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 73.BRAZIL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 74.BRAZIL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 75.BRAZIL CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 76.MEXICO CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 77.MEXICO CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 78.MEXICO CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 79.MEXICO CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 80.MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION) TABLE 81.MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 82.MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) TABLE 83.MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION) FIG 1.GLOBAL CANCER/TUMOR PROFILING MARKET, RESEARCH METHODOLOGY FIG 2.GLOBAL CANCER/TUMOR PROFILING MARKET, MARKET ESTIMATION TECHNIQUES FIG 3.GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS FIG 4.GLOBAL CANCER/TUMOR PROFILING MARKET, KEY TRENDS 2017 FIG 5.GLOBAL HEAT EXCHANGERS, GROWTH PROSPECTS 2018-2026 FIG 6.GLOBAL CANCER/TUMOR PROFILING MARKET, PORTERS 5 FORCE MODEL FIG 7.GLOBAL CANCER/TUMOR PROFILING MARKET, PEST ANALYSIS FIG 8.GLOBAL CANCER/TUMOR PROFILING MARKET, VALUE CHAIN ANALYSIS FIG 9.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 10.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 11.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 12.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 13.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 14.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 15.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 16.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 17.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 18.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 19.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 20.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 21.GLOBAL CANCER/TUMOR PROFILING MARKET BY SEGMENT, 2016-2026 (USD BILLION) FIG 22.GLOBAL CANCER/TUMOR PROFILING MARKET, REGIONAL SNAPSHOT 2016-2026 FIG 23.NORTH AMERICA CANCER/TUMOR PROFILING MARKET 2016-2026 (USD BILLION) FIG 24.EUROPE CANCER/TUMOR PROFILING MARKET 2016-2026 (USD BILLION) FIG 25.ASIA PACIFIC CANCER/TUMOR PROFILING MARKET 2016-2026 (USD BILLION) FIG 26.LATIN AMERICA CANCER/TUMOR PROFILING MARKET 2016-2026 (USD BILLION) FIG 27.ROW CANCER/TUMOR PROFILING MARKET 2016-2026 (USD BILLION) FIG 28.GLOBAL CANCER/TUMOR PROFILING MARKET, COMPANY MARKET SHARE ANALYSIS (2016)
01
Project Kick-off
Getting the research team on board discussing research objective, research scope, methodology, timeline and challenges
02
Desk Research
Developing Contact lits,Questionnaires,and market models Conducting desk research through credible publishedsources to collect relevant qualitative & quantitative data in relation to the research objectives
03
Primary Research
Conducting interviews with key opinion leaders ( KOLs ) and stakeholders to derve data in relationto the research objective and validate market numbers estimated through market models and industry-leading research tool
04
Analysis & Report Writing
Analysing the data sourced via desk and primary research and building report, conclusions,& recommendations sed on research objective
Industry Research Insights follows a robust research methodology that involves data triangulation based on top-down, bottom-up approaches, and validation of the estimated market numbers through primary research. The information used to estimate the market size and forecast for various segments at the global, regional, and country level is derived from the most credible published sources and through interviews with the right stakeholders.
Growth rate or CAGR exhibited by a market for a certain forecast period is calculated on the basis of various factors and their level of impact on the market. These factors include market drivers, restraints, industry challenges, market and technological developments, market trends, etc.
Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
Industry journals and paid databases
Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
Number of procedures and average price of procedures
Replacement rate and pricing of capital equipment
Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
Market & technological trends, new product developments, product pipeline.
Detailed product mappping of all Major and small players operating in the market
Estimmation of revenues/market size of all segments to arrive at the total market
Estimmates based on prevalence of diseases,diagnosed and treated patients numbers, product demand, and average annual spending on treatment
Estimates based on number of users end average consumption/spending by end users
Estimates based on number of procedures and average number of devices\consumables used per procedure
Top-down approach based on the data published on revenues, market share and growth rate of major players operating in the market
Discussions with key opinion leaders(KOLs) and stakeholders to validates market estimates and get their insights in relation to trends, dyanamics and competitive analysis
Key stakeholders such as purchasing managers, nurses, pharmacists, surgeons, physicians, etc. in end-use facilities such as hospitals, clinics, ambulatory surgery centers, pharmacies, research institutes, etc.
Key opinion leaders in related associations
Key stakeholders such as C-level executives, marketing managers, product managers, sales managers, etc. in major companies (suppliers and distributors) operating in the market
Insights from supply side respondents in relation to the market size, growth rate, market distribution, market dynamics, and market share analysis
Validation of the market size, growth rate, and market distribution estimated on the basis of market models
nsights from end user respondents to feed into models such as patient/procedure numbers, distribution of patients by treatment type, average pricing, average spending on devices, replacement rate of capital equipment, etc.
Illumina, Inc. Qiagen N.V. Neogenomics Laboratories, Inc. HTG Molecular Diagnostics, Inc. Genomic Health Inc. Caris Life Sciences Helomics Corporation Nanostring Technologies, Inc. Oxford Gene Technology Ribomed Biotechnologies, Inc.
Review
Industry & Research is a safe and trustful bridge which connect clients to data, insights and market research professionals, to achieve reliable results.
3M
I&R did an outstanding job on the Global Automotive Catalyst Market project. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Leading Chemical industry-France
The information in the 'Military Aircraft Health Monitoring System' study was very well appreciated. The customer centric and friendly approach by such a large market research firm is what differentiates you from your competitors
Leading Defense Industry-Privacy Requested
Our Clients
2019-07-10
Our team of researchers are studying COVID 19 and its impact on various industry verticals and wherever required we will be considering COVID-19 footprints for better analysis of markets and industries.